Medical

Grifols has announced that its inhaled alpha1-proteinase inhibitor received orphan drug designation from the FDA in April 2012 and that the company will begin a safety study of the drug by the end of the… Read more . . .

GlaxoSmithKline and Theravance have announced results from four Phase 3 studies of its umeclidinium bromide (UMEC)/vilanterol (VI) combination DPI for the treatment of COPD. The studies include two 24-week efficacy studies and two 24-week active… Read more . . .

Regency Therapeutics has announced the initiation of the 18-month AMPED (Acute Management of Pain from the Emergency Department) registry study to compare patient response to Sprix ketorolac tromethamine nasal spray used to treat pain in… Read more . . .

Civitas Therapeutics has announced the initiation of a Phase 2a clinical trial of its CVT-301 inhaled L-dopa for the treatment of motor fluctuations in patients with Parkinson’s disease. CVT-301 is formulated and delivered using the… Read more . . .

Alnylam Pharmaceuticals says that its ALN-RSV01 inhaled RNAi drug failed to meet the primary endpoint of a Phase 2b study, not significantly reducing the incidence of bronchiolitis obliterans syndrome (BOS) at 180 days after infection… Read more . . .

Boehringer Ingelheim has presented data from studies of olodaterol and tiotropium at the 2012 Annual Meeting of the American Thoracic Society. According to the company, it has now completed its Phase 2 trials of olodaterol,… Read more . . .

US Health and Human Services Secretary Kathleen Sebelius has announced a national plan to fight Alzheimer’s disease that includes almost $8 million in funding for research related to an insulin nasal spray for the treatment… Read more . . .

Elevation Pharmaceuticals has announced that a Phase 2b study of its EP-101 glycopyrrolate inhalation solution in patients with moderate to severe COPD demonstrated that EP-101 produced statistically significant improvement in lung function compared to placebo… Read more . . .